I'm glad you brought this up - I need to ask my current prescriber about this. When I first went on venlafaxine, there was no generic option in the US for desvenlafaxine. There was only name-brand pristiq, and it was definitely not going to be covered by my insurance unless I did another trial of an SSRI, which would have been a difficult waste of time (basically repeating something I had to do a few years before). There's a generic available now, and I should see if my psych wants to think about switching. Not sure it would be a 'go' for me, as I'm on an extremely high dose of effexor, and I don't think pristiq has been cleared yet to be used at an equivalent dose. Then again, there's not necessarily any clinical reason for the high effexor dose, except for I think one study that showed some increased efficacy for ultra-rapid metabolizers at higher doses.Thought I’d throw that in for people who are finding benefits from Effexor but hate the side effects.
I had a very problematic response to Abilify. Psychiatrically, it was wonderful. Worked amazingly well. Didn't lift my mood, but absolutely took care of lifting up the bottom of the depression.the meds you’ve trialled seem really light on atypical antipsychotics. Is that for any specific reason?
And, I had a continual significant weight gain that would not stop, despite trying multiple ways of dealing with it. I'm pretty confident it was the medication, simply because there was nothing else that changed in my food or exercise patterns - I just started gaining weight. Ate less, exercised more, still gained weight. Tried dropping the med, tried some alternatives, but they had other problems....So I was on it for about 2+ years, give or take, until I was able to stop work for a significant period of time and try something else.
Since then, there's been some interesting research into atypical antipsychotics and metabolic changes. The frustrating part (of course) is that abilify is supposed to be weight-neutral. The percentage of people affected by weight gain while on it is very very low. So...it's not something that anyone is really actively working to correct in some other formulation.